Overview of This Study:
The study involved four major activities to estimate the current size of the patient blood management market. Exhaustive secondary research was done to collect information on the market and its different subsegments.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.
Geographical Growth Scenario:
The Asia Pacific market is expected to grow at the highest CAGR during the forecast period
The market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. China and India are expected to offer significant growth opportunities for players in the market, mainly due to the rising patient pool, growing support from government bodies, and the rising awareness about blood transfusion. The governments in these countries are making significant investments toward the modernization of their respective healthcare infrastructure, which will greatly benefit the market.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131352979
Globally, the demand for donated blood is increasing because of greater volume of sophisticated medical surgical procedures conducted and the increasing number of trauma cases due to road accidents. These procedures require blood transfusions to make up for blood loss incurred during the procedures. Thus, the rising number of accidents, trauma cases, and surgical procedures performed are contributing to the market growth, thereby increasing the need for patient blood management products.
End Users:
The blood banks end user segment garnered the highest revenue in the patient blood management market in 2019
Based on end users, the market is segmented into hospitals and blood banks. The blood bank segment accounted for the largest share of the market in 2019; moreover, the same segment is expected to register significant growth over the forecast period from 2019 to 2024. The significant growth of this segment is attributed to the increasing awareness of blood donations , the high demand for safe blood, and the rising number of blood donations.
Recent Developments:
# In 2019, Abbott (US) received the US FDA approval for its ‘Alinity s’ blood culture screening system as well as the Afinion HbA1c Dx assay kit.
# In 2019, F. Hoffmann-La Roche LTD (Switzerland) received the US FDA approval for its cobas Babesia Test for donor screening.
# In 2018, Terumo BCT (Japan) and Stafa Cellular Therapy (US) entered into a collaborative agreement. Based on this agreement, Terumo BCT expands access to the StafaCT software to healthcare organizations.
# In 2018, B. Braun Melsungen AG (Ireland) acquired the bloodlines business of NxStage Medical, Inc. (US), which operates under the Medisystems brand.
# In 2018, Abbott (US) received a CE mark for its Alinity h-series to be used in the European Union.
Key Players:
The major players in the market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMérieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche LTD (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc. (Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=131352979
